Belgian nanobody developer Ablynx NVs nanobody caplacizumab has met relevant endpoints in the pivotal Hercules Phase III study in patients with thrombotic thrombocytopenic purpura (aTTP), paving the way to market authorisation in Europe and the US.
https://european-biotechnology.com/wp-content/uploads/2024/04/Jesper_Ericsson.jpeg8531280h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2017-09-29 11:49:482017-09-29 11:49:48Jesper Ericsson named new Chief Executive Officer by Symcell Sverige AB
A newly-developed, fast, and cost-effective dipstick test sensitively and specifically identified Zika virus and all four dengue virus subtypes without any detectable cross-reactivity.
The Spanish biotech sector is growing. This attracts more and more international investors. End of September ASEBIO organised the first edition of an Investor Day.
https://european-biotechnology.com/wp-content/uploads/2024/04/2017_2809_asebio_investorday.jpg444800Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-09-28 10:22:002017-09-28 10:22:00Why to watch out Spain
Danish Genmab A/S has received market approval in Japan for its anti-CD38 antibody daratumumab (DARZALEX®) as therapy for relapsed or refractory Multiple Myeloma.
Neurology specialistNewron Pharmaceuticals S.p.A. (Milan) has raised gross proceeds of CHF 27m through a private placement of new shares via an accelerated book-building process.
Though not reaching the overall surival endpoint in Phase III, the European Commission has granted label extension for Roches checkpoint blocker Tecentriq in two types of metastatic bladder cancer.
French microbiota specialist Da Volterra has received an EIB loan to speed up development of treatments that prevent antibiotic resistance and hospital acquired infections.
Ablynx takes Phase III hurdle in acquired TTP
Latest NewsBelgian nanobody developer Ablynx NVs nanobody caplacizumab has met relevant endpoints in the pivotal Hercules Phase III study in patients with thrombotic thrombocytopenic purpura (aTTP), paving the way to market authorisation in Europe and the US.
MD8 Airscan®
ProductsActive sampling of airborne viruses, bacteria, yeasts and fungi.
Jesper Ericsson named new Chief Executive Officer by Symcell Sverige AB
AppointmentsSymcel announced that Jesper Ericsson has joined Symcel as Chief Executive Officer.
Dipstick test detects Zika
Latest NewsA newly-developed, fast, and cost-effective dipstick test sensitively and specifically identified Zika virus and all four dengue virus subtypes without any detectable cross-reactivity.
Why to watch out Spain
Latest NewsEvotec acquires stake in Exscientia
Latest NewsGerman CRO Evotec AG announced an €15m investment in British Exscienta Ltd. to push artificial intelligence (AI)-driven drug discovery.
Genmab bags €25m milestone upon market approval of daratumumab
Latest NewsDanish Genmab A/S has received market approval in Japan for its anti-CD38 antibody daratumumab (DARZALEX®) as therapy for relapsed or refractory Multiple Myeloma.
Newron raises CHF27m
Latest NewsNeurology specialist Newron Pharmaceuticals S.p.A. (Milan) has raised gross proceeds of CHF 27m through a private placement of new shares via an accelerated book-building process.
EU approves Roches atezolizumab for bladder cancer
Latest NewsThough not reaching the overall surival endpoint in Phase III, the European Commission has granted label extension for Roches checkpoint blocker Tecentriq in two types of metastatic bladder cancer.
Da Volterra bags €20m EIB investment
Latest NewsFrench microbiota specialist Da Volterra has received an EIB loan to speed up development of treatments that prevent antibiotic resistance and hospital acquired infections.